InflaRx Sponsored Session: For Some Patients, COVID-19 Remains A Serious Threat
Includes a Live Web Event on 09/25/2024 at 12:55 PM (PDT)
Description:
Date/Time: September 25, 2024 | 3:55 - 4:10 pm ET
This sponsored session will focus on the current demographics of patients who are at risk of developing pneumonia, sepsis, and acute respiratory distress syndrome (ARDS) in response to SARs-CoV-2 infection. The pathophysiology of COVID-19 will be described focusing on the involvement of the complement cascade responding to infection and how Gohibic® (vilobelimab) has an emergency use authorization for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation (IMV), or extracorporeal oxygenation (ECMO).
Target Audience:
Nurses, advanced practice providers, physicians, emergency responders, pharmacists, medical technologists, respiratory therapists, physical/occupational therapists, infection prevention specialists, data/quality specialists, and more.
Bruce P. Burnett, PhD
VP, Head of Medical Affairs
InflaRx
Bruce P. Burnett, PhD, joined InflaRx in 2020 as Head of US Regulatory and Medical Affairs. He received his BS degrees in biology and chemistry from Eastern Washington University and his master's in philosophy in biochemistry and PhD in molecular biophysics and biochemistry from Yale University. He received several NIH and SBIR grants and has served on the ad hoc study section for review of NIH SBIR awards. Dr. Burnett has been in the pharmaceutical industry for over 25 years, spending his first 8 years in drug discovery and then the last 17 in medical affairs, regulatory and compliance. His disease state experience includes women’s health (contraception, HRT-menopausal symptom relief, aesthetics-venous disease, osteopenia/osteoporosis), gastroenterology (irritable bowel syndrome, HIV-enteropathy, Crohn’s disease, ulcerative colitis, chronic diarrhea, GERD), rheumatology (osteoarthritis, rheumatoid arthritis), vascular disease (ANCA-AAV, chronic venous insufficiency, deep vein thrombosis and hemorrhoids), dermatology (hidradenitis suppurativa, pyoderma grangenosum, cutaneous squamous cell carcinoma, superficial bacterial and fungal infections, pruritus, acne, plaque psoriasis), infectious disease (HIV, GI infections-H. pylori and C. difficile, endemic/systemic fungal infections) and pulmonology (COVID-19, antifungal prophylaxis in lung and bone marrow transplant patients). Dr. Burnett supports the development of new chemical entities as well as collaboration with the clinical department to advance InflaRx’s clinical programs through interactions with thought leaders in each field.
Summit 2024 Session: InflaRx Sponsored Session: For Some Patients, COVID-19 Remains A Serious Threat
Session Day/Time: Wednesday, September 25, 2024, 3:55 PM - 4:10 PM EST